ArticleViruses2021
A 10-Minute "Mix and Read" Antibody Assay for SARS-CoV-2.
Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors.The Journal of infectious diseases · 2023Trial
- Scent dogs in detection of COVID-19: triple-blinded randomised trial and operational real-life screening in airport setting.BMJ global health · 2022Trial
- Anti-spike IgG Avidity Enhances Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2: A Prospective Study of Primary Infections and Immunizations.The Journal of infectious diseases · 2026Article
- SARS-CoV-2 infection in hiPSC-derived neurons is cathepsin-dependent and causes differential accumulation of HIF1ɑ and phosphorylated tau.Molecular therapy. Nucleic acids · 2025Article
- Development of a New Indirect ELISA Test for the Detection of Anti-Feline Coronavirus Antibodies in Cats.Veterinary sciences · 2025Article
- A New Rapid Indirect ELISA Test for Serological Diagnosis of Feline Immunodeficiency.Veterinary sciences · 2025Article
- Evaluation of a newly developed rapid ELISA to detect anti-Ehrlichia canis antibodies in dogs.Parasite (Paris, France) · 2025Article
- Convalescent plasma therapy for COVID-19 - Donor selection strategies and establishment of a plasma bank.New microbes and new infections · 2024Article
- Time-Dependent Effective Hamiltonians for Light-Matter Interactions.Entropy (Basel, Switzerland) · 2024Article
- Whole Blood as a Sample Matrix in Homogeneous Time-Resolved Assay-Förster Resonance Energy Transfer-Based Antibody Detection.Diagnostics (Basel, Switzerland) · 2024Article
- Atomic/molecular layer deposition of europium-organic thin films on nanoplasmonic structures towards FRET-based applications.Nanoscale · 2023Article
- Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2.Cell reports methods · 2023Article
- Article
- Stable Levels of Antibodies Against Unrelated Toxoid Vaccines After COVID-19: COVID-19 Infection Does Not Affect Toxoid Vaccine Antibody Levels.Pathogens & immunity · 2023Article
- Persistent Reptarenavirus and Hartmanivirus Infection in Cultured Boid Cells.Microbiology spectrum · 2022Article
- Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection.International journal of molecular sciences · 2022Article
- World Society for Virology first international conference: Tackling global virus epidemics.Virology · 2022Article
- Article
- Article
- AC2: An Efficient Protein Sequence Compression Tool Using Artificial Neural Networks and Cache-Hash Models.Entropy (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 3 countries.
Funding
Abstract
Accurate and rapid diagnostic tools are needed for management of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Antibody tests enable detection of individuals past the initial phase of infection and help examine vaccine responses. The major targets of human antibody response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are the spike glycoprotein (SP) and nucleocapsid protein (NP). We have developed a rapid homogenous approach for antibody detection termed LFRET (protein L-based time-resolved Förster resonance energy transfer immunoassay). In LFRET, fluorophore-labeled protein L and antigen are brought to close proximity by antigen-specific patient immunoglobulins of any isotype, resulting in TR-FRET signal. We set up LFRET assays for antibodies against SP and NP and evaluated their diagnostic performance using a panel of 77 serum/plasma samples from 44 individuals with COVID-19 and 52 negative controls. Moreover, using a previously described SP and a novel NP construct, we set up enzyme linked immunosorbent assays (ELISAs) for antibodies against SARS-CoV-2 SP and NP. We then compared the LFRET assays with these ELISAs and with a SARS-CoV-2 microneutralization test (MNT). We found the LFRET assays to parallel ELISAs in sensitivity (90-95% vs. 90-100%) and specificity (100% vs. 94-100%). In identifying individuals with or without a detectable neutralizing antibody response, LFRET outperformed ELISA in specificity (91-96% vs. 82-87%), while demonstrating an equal sensitivity (98%). In conclusion, this study demonstrates the applicability of LFRET, a 10-min "mix and read" assay, to detection of SARS-CoV-2 antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.